Net Assets for AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's latest reported net assets is $48.67B USD. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
AZN
Currently viewingRevenueSwitch metric
Latest period
$48.67B
YoY change
+19.3%
5Y CAGR
+25.5%
Peak year (2025)
$48.67B
Latest annual
$48.67B
Net Assets history chart for AstraZeneca (AZN) from 1990 to 2025
Net Assets history table for AstraZeneca (AZN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Net Assets | YoY |
|---|---|---|---|---|
| 2025 | $48.67B | +19.3% | ||
| 2024 | $40.79B | +4.2% | ||
| 2023 | $39.14B | +5.7% | ||
| 2022 | $37.04B | -5.7% | ||
| 2021 | $39.27B | +151.4% | ||
| 2020 | $15.62B | +19.0% | ||
| 2019 | $13.13B | +5.3% | ||
| 2018 | $12.47B | -16.7% | ||
| 2017 | $14.96B | +0.7% | ||
| 2016 | $14.85B | -19.7% | ||
| 2015 | $18.49B | -5.8% | ||
| 2014 | $19.63B | -15.5% | ||
| 2013 | $23.22B | -2.2% | ||
| 2012 | $23.74B | +2.1% | ||
| 2011 | $23.25B | +0.1% | ||
| 2010 | $23.21B | +12.4% | ||
| 2009 | $20.66B | +29.8% | ||
| 2008 | $15.91B | +7.7% | ||
| 2007 | $14.78B | -3.4% | ||
| 2006 | $15.30B | +12.6% | ||
| 2005 | $13.60B | -5.6% | ||
| 2004 | $14.40B | +9.3% | ||
| 2003 | $13.18B | +18.0% | ||
| 2002 | $11.17B | -18.5% | ||
| 2001 | $13.71B | +43.9% | ||
| 2000 | $9.53B | -7.5% | ||
| 1999 | $10.30B | +146.8% | ||
| 1998 | $4.17B | +16.9% | ||
| 1997 | $3.57B | +2.5% | ||
| 1996 | $3.48B | +21.1% | ||
| 1995 | $2.88B | +9.2% | ||
| 1994 | $2.63B | +18.8% | ||
| 1993 | $2.22B | +2558.1% | ||
| 1992 | $83.42M | -89.3% | ||
| 1991 | $782.16M | +37.0% | ||
| 1990 | $570.97M | — |
Net Assets values are taken from AstraZeneca's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual net assets for AstraZeneca (AZN) came in at $48.67B – grew 19.3% year-over-year.
Looking at the 2020–2025 (5 years) stretch, AstraZeneca net assets compounded at +25.5% per year, sustaining 3 straight years of year-over-year growth.
2025 marks the peak net assets at $48.67B, with the historical low of $83.42M recorded in 1992.
Among 8 Healthcare peers, AstraZeneca (AZN) ranks 6th; the peer median for net assets is $53.01B.
AstraZeneca Net Assets by Year
AstraZeneca Net Assets 2025: $48.67B
AstraZeneca net assets in 2025 was $48.67B, grew 19.3% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca Net Assets 2024: $40.79B
AstraZeneca net assets in 2024 was $40.79B, edged up 4.2% from 2023.
AstraZeneca Net Assets 2023: $39.14B
AstraZeneca net assets in 2023 was $39.14B, grew 5.7% from 2022.
AstraZeneca Net Assets 2022: $37.04B
AstraZeneca net assets in 2022 was $37.04B, declined 5.7% below 2021.
AstraZeneca Net Assets 2021: $39.27B
AstraZeneca net assets in 2021 was $39.27B.
See more financial history for AstraZeneca (AZN).
Sector peers — Net Assets
Companies in the same sector as AstraZeneca, ranked by their latest net assets.
| Company | Net Assets | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $194.05B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $94.11B | Healthcare |
| Johnson & Johnson (JNJ) | $81.54B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $53.41B | Healthcare |
| Merck & Co., Inc. (MRK) | $52.61B | Healthcare |
| Eli Lilly and Company (LLY) | $26.54B | Healthcare |
| Amgen Inc. (AMGN) | $8.66B | Healthcare |
| AbbVie Inc. (ABBV) | -$3.27B | Healthcare |
Frequently asked questions
What is AstraZeneca's net assets?
- Latest reported net assets for AstraZeneca (AZN) is $48.67B (period ending December 31, 2025).
How has AstraZeneca net assets changed year-over-year?
- AstraZeneca (AZN) net assets changed +19.3% year-over-year on the latest annual filing.
What is the long-term growth rate of AstraZeneca net assets?
- AstraZeneca (AZN) net assets compound annual growth rate is +25.5% over the most recent 5 years available.
When did AstraZeneca net assets hit its highest annual value?
- AstraZeneca net assets reached its highest annual value of $48.67B in 2025.
What was AstraZeneca net assets in 2024?
- AstraZeneca (AZN) net assets in 2024 was $40.79B.
What was AstraZeneca net assets in 2025?
- AstraZeneca (AZN) net assets in 2025 was $48.67B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
AZN Overview
Company profile, financial tools, and key metrics
AZN Revenue Counter
Earns $1,863 every second. See per minute, hour, and day.
AZN Earnings Counter
Earns $324.23 per second net profit. See per minute, hour, and day.
AZN Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
AZN What If Invested
What if you had invested $1,000? See historical returns from any date.
AZN How It Makes Money
Discover visual breakdown of $58.74B in revenue — where it comes from and where it goes.
AZN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
AZN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
AZN Daily Price Character
Steady · 49.4% historical win rate (green days). Streaks & record days.
AZN Buybacks
0.16% TTM buyback yield. Shareholder yield & SBC comparison.
AZN Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
AZN Dividend Profile
Yield: 1.73%. Safety: 6/8. See full history.
AZN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
AZN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.